Beta Bionics Chief Commercial Officer Mark Hopman sold 30,779 shares at $20.13 each on 2026-09-16. The post-sale position was 56,479 shares in Beta Bionics, and the transaction equalled about 35.3% of his prior holding.
Key Highlights
- Mark Hopman’s transaction represented about 35.3% of his prior Beta Bionics shareholding.
- The Beta Bionics executive retained 56,479 shares after the transaction.
- The reported trade was priced at $20.13 per share.
Mark Hopman, the company’s Chief Commercial Officer, sold 30,779 shares on 16 September 2026 at $20.13 each, leaving him with 56,479 shares.
Beta Bionics (NASDAQ: BBNX) Sale Details
The transaction occurred on 16 September 2026, with each of the 30,779 shares priced at $20.13. His remaining position was 56,479 Beta Bionics (NASDAQ: BBNX) shares after the sale.
35.3% of Prior Holding Sold
About 35.3% is the stated measure for the portion of Hopman’s prior holding represented by the transaction. The percentage refers to the position before the sale, while the share count describes what he held afterward.
FAQs
Q: How many Beta Bionics shares did Mark Hopman sell?
A: Mark Hopman sold 30,779 Beta Bionics shares. The reported sale price was $20.13 per share.
Q: How many BBNX shares did Mark Hopman own after the sale?
A: Mark Hopman owned 56,479 Beta Bionics shares after the transaction. The figure represents his disclosed post-sale holding.
Q: What percentage of Mark Hopman’s prior BBNX holding did the sale represent?
A: The transaction represented about 35.3% of Hopman’s prior shareholding in Beta Bionics. The reported post-sale balance was 56,479 shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.